Universal Cancer Peptide-based Vaccination in Metastatic NSCLC

Inclusion Criteria: * Written informed consent * Histologically or cytologically confirmed NSCLC (adenocarcinoma, squamous cell carcinoma, large cell carcinoma, undifferentiated carcinoma or other) * Stage IIIB not amenable to radiotherapy or stage IV cancer according to the TNM classification (7th edition) or recurrent NSCLC after surgery not amenable to loco-regional therapy. * Pre-treated with at least 2 or 3 lines of treatment (including immunotherapy). Chemoradiation for stage IIIB disease is considered as one treatment line. * At least one measurable lesion by CT scan or MRI based on RECIST criteria version 1.1 * Performance status 0 or 1 on the ECOG scale * Life-expectancy \> 3 months * Adequate hematological, hepatic, and renal function Exclusion Criteria: * Prior history of other malignancy except for: basal cell carcinoma of the skin, cervical intra-epithelial neoplasia and other cancer curatively treated with no evidence of disease for at least 5 years * Symptomatic brain metastases. Patients with controlled brain metastases after radiation therapy or with asymptomatic brain metastases may be included. * History of active autoimmune diseases (lupus, rheumatoid arthritis, inflammatory bowel disease…) * Patients under chronic treatment with systemic corticoids or other immunosuppressive drugs (prednisone or prednisolone ≤ 10 mg/day is allowed) - - Positive serology for Human Immunodeficiency Virus (HIV) or Hepatitis C virus (HCV); presence in the serum of the antigens HBs * Participation in a clinical study with an investigational product within 4 weeks prior to the start of the study treatment * Pregnancy or lactating patients. * Patients with any medical or psychiatric condition or disease, * Patients under guardianship, curatorship or under the protection of justice.